[Potential of non-coding RNA as biomarkers in heart failure].
Heart failure is a major public health problem with an estimated prevalence of 1-2% in the adult population in developed countries. Despite some progress, the prognosis of heart failure is associated with high mortality. There is a need for prognostic markers for heart failure, such as circulating biomarkers, in order to better identify individual heart failure patients with high risk of early death, and to improve the selection of patients for invasive treatment with limited availability such as heart transplantation. Among the non coding RNA family, we investigated the potentiality of long non coding RNAs (lncRNA) as potential biomarkers in heart disease. We observed that the plasmatic levels of the lncRNA named LIPCAR may predict early mortality in patients with heart failure independently of the etiology and may improve clinical-decision making for a more personalized treatment of "high-risk" patients.
Inserm U1167, Institut Pasteur de Lille, université de Lille, CHRU de Lille, faculté de médecine, 1, rue du Professeur Calmette, 59019 Lille, France.
Florence
F
Pinet
Inserm U1167, Institut Pasteur de Lille, université de Lille, CHRU de Lille, faculté de médecine, 1, rue du Professeur Calmette, 59019 Lille, France.
Christophe
C
Bauters
D015415:Biomarkers / Q000097:blood; D006333:Heart Failure / Q000097:blood*; D006801:Humans; D062085:RNA, Long Noncoding / Q000097:blood*
D015415:Biomarkers; D062085:RNA, Long Noncoding